CD274 and neoplasm: Moreover, a single dose of PD1-41BB-expressing PRAME T-cells achieved in vivo tumor control of an aggressively growing xenograft with low antigen density and high expression of PD-L1 that was resistant to eradication by T-cells only expressing the highly potent PRAME TCR.